

Jennifer Leohr Bs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/207739/publications.pdf>

Version: 2024-02-01

16
papers

195
citations

1306789

7
h-index

1125271

13
g-index

16
all docs

16
docs citations

16
times ranked

136
citing authors

#	ARTICLE	IF	CITATIONS
1	Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study. Diabetes, Obesity and Metabolism, 2022, 24, 196-203.	2.2	6
2	Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study. Diabetes, Obesity and Metabolism, 2022, 24, 187-195.	2.2	6
3	Impact of Obesity on Postprandial Triglyceride Contribution to Glucose Homeostasis, Assessed with a Semimechanistic Model. Clinical Pharmacology and Therapeutics, 2022, 112, 112-124.	2.3	2
4	Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites. Clinical Therapeutics, 2022, , .	1.1	0
5	Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data. Clinical Pharmacokinetics, 2021, 60, 1423-1434.	1.6	19
6	Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 815-823.	0.8	1
7	Postprandial triglyceride reduction following acute treatment of a selective 5-hydroxytryptamine _{2c} agonist and characterization using a semi-physiological model. Diabetes, Obesity and Metabolism, 2021, 23, 1001-1010.	2.2	1
8	Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. Clinical Therapeutics, 2020, 42, 1762-1777.e4.	1.1	12
9	Sweet/Fat Preference Taste in Subjects Who are Lean, Obese and Very Obese. Pharmaceutical Research, 2020, 37, 244.	1.7	5
10	Pharmacokinetics and Glucodynamics of Ultra-Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial. Clinical Pharmacokinetics, 2020, 59, 1589-1599.	1.6	47
11	Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects. Diabetes Therapy, 2020, 11, 1709-1720.	1.2	3
12	Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clinical Pharmacokinetics, 2020, 59, 1601-1610.	1.6	27
13	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes, Obesity and Metabolism, 2020, 22, 1789-1798.	2.2	49
14	1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D. Diabetes, 2019, 68, .	0.3	7
15	Semi-physiological model of postprandial triglyceride response in lean, obese and very obese individuals after a high-fat meal. Diabetes, Obesity and Metabolism, 2018, 20, 660-666.	2.2	3
16	Ultra-rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T1D at Multiple Meal-to-Dose Timing Intervals. Diabetes, 2018, 67, .	0.3	7